Compositions and method of making a complex able to increase production of a cetuximab-like protein (CLP) in a target cell
The present disclosure relates to one or more agents, therapies, treatments, and methods of use of the agents and/or therapies and/or treatments for increasing production of a Cetuximab-like protein (CLP) by a subject that is administered the agent, therapy or treatment. Embodiments of the present disclosure can be used as a therapy or a treatment for a subject that has a condition that may benefit from reducing the DNA synthesis of genes that regulate cellular growth and proliferation.
1. A composition that comprises a nucleotide sequence according to SEQ ID No. 9 that can be expressed in a target cell.
2. A pharmaceutical composition comprising a nucleotide sequence according to SEQ ID No. 9 and one or more pharmaceutically acceptable carriers and/or one or more excipients.
3. A method of making an agent/target cell complex, the method comprising a step of administering a nucleotide sequence according to SEQ ID No. 9 to a target cell for forming the agent/target cell complex, wherein the agent/target cell complex causes the target cell to increase production of a Cetuximab-like protein (CLP).
4. The method of claim 3 , wherein the target cell is one or more of an adrenal gland cell; a bile duct cell; a chondrocyte; a cochlear cell; a corneal cell; an endocardium cell; an endometrial cell; an endothelial cell; an epithelial cell; a fibroblast; a hair follicle cell; a hepatocyte; a lymph node cell; a mucosal cell; a myocyte; a neuron; a glomeruli cell; an optic nerve cell; an osteoblast; an ovarian tissue cell; a pancreatic islet beta cell; a pericardium cell; a platelet; a red blood cell (RBC); a retinal cell; a scleral cell; a Schwann cell; a T cell; a testicular tissue cell; a thyroid gland cell; a uveal cell; a tumor cell, and combinations thereof.